SLC5A2 and type 2 diabetes mellitus: A better understanding of the comparative effectiveness of SGLT2 inhibitors vs sulfonylureas associated with all-cause mortality (a terminal outcome that encompasses the breadth of potential SGLT2 inhibitor benefits) might guide a more informed choice of antihyperglycemic therapy in people with type 2 diabetes.